[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.216.242. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
December 27, 2000

Safety of Celecoxib vs Other Nonsteroidal Anti-inflammatory Drugs—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor

JAMA. 2000;284(24):3123-3124. doi:10.1001/jama.284.24.3123

In Reply: While we agree with Dr Köhler and colleagues that the CLASS trial supports the hypothesis that COX-2–specific inhibitors will produce fewer ulcers and ulcer complications than conventional NSAIDs, we disagree that the data suggest the possibility that celecoxib interferes with healing of aspirin-induced GI mucosal lesions. A prior study1 has found that the relative risk of an ulcer complication in aspirin users vs nonaspirin users is approximately the same as the relative risk of an ulcer complication in aspirin users receiving celecoxib vs nonaspirin users receiving celecoxib that we reported.

First Page Preview View Large
First page PDF preview
First page PDF preview
×